본문 바로가기
investors

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

2024.01.02

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

LegoChem Biosciences to receive up to potentially USD1.7 billion in total, including upfront payment and option exercise fee

 

 

DAEJEON, Korea, Dec. 26, 2023  --  LegoChem Biosciences, Inc. (141080KS:LCB) announced on December 26 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize  LCB84, a Trop2 directed antibody drug conjugate (ADC).

 

Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84. LCB is eligible for up to potentially USD 1.7 billion in total consideration including an upfront payment of USD 100 million, an option exercise payment of USD 200 million as well as potential development, regulatory and commercial milestone payments, plus tiered royalties on net sales. The companies will collaborate during the ongoing Phase 1/2 clinical trial, with Janssen being solely responsible for clinical development and commercialization after option exercise.

 

LCB84, a Trop2 directed ADC applying LCB’s next-generation ADC platform technology and Trop2 antibody licensed from Mediterranea Theranostic, S.r.l, is being studied in a recently initiated Phase 1/2 clinical trial in the U.S. The ADC has a distinctive targeted mechanism, binding a unique cleaved form of the Trop2 antigen, which is highly expressed in cancer cells. Preclinical data demonstrated a differentiated safety and efficacy profile compared across multiple cancers, showing LCB84’s promise as a Trop2-targeting ADC.

 

“We are very pleased to collaborate with Janssen on LCB84, our first wholly in-house developed clinical stage ADC,” said Yong-Zu Kim, President and CEO of LCB. “We look forward to continuing to build our global clinical development capabilities and advance other ADC programs into clinic.”